Myocardial stunning following no flow ischaemia is diminished by levosimendan or cariporide, without benefits of combined administration

Resuscitation

Volumn 76, Issue 1, 2008, Pages 95-102

  Brendt, Peter ^a   Behrends, Matthias ^a   Peters, Jürgen ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Cariporide; Guinea pig; Ischaemia reperfusion; Isolated heart; Levosimendan; Myocardial function; Stunning

Indexed keywords

CARIPORIDE; LEVOSIMENDAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; GUINEA PIG; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; STUNNED HEART MUSCLE;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; GUANIDINES; GUINEA PIGS; HYDRAZONES; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIAL STUNNING; PROSPECTIVE STUDIES; PYRIDAZINES; RANDOM ALLOCATION; SULFONES;

EID: 36849094475     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2007.06.029     Document Type: Article

References (50)

1. Braunwald E., and Kloner R.A. The stunned myocardium: prolonged, post-ischemic ventricular dysfunction. Circulation 66 (1982) 1146-1149
2. Roberts A.J., Spies S.M., Meyers S.N., et al. Early and long-term improvement in left ventricular performance following coronary bypass surgery. Surgery 88 (1980) 467-475
3. Ruiz-Bailen M., Aguayo de Hoyos E., Ruiz-Navarro S., et al. Reversible myocardial dysfunction after cardiopulmonary resuscitation. Resuscitation 66 (2005) 175-181
4. Laurent I., Monchi M., Chiche J.D., et al. Reversible myocardial dysfunction in survivors of out-of-hospital cardiac arrest. J Am Coll Cardiol 40 (2002) 2110-2116
5. 2+ exchange system in the pathogenesis of myocardial ischemia-reperfusion damage. Sci China B 34 (1991) 599-605
6. Scholz W., Albus U., Counillon L., et al. Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion. Cardiovasc Res 29 (1995) 260-268
7. Kristo G., Yoshimura Y., Ferraris S.P., Jahania S.A., Mentzer Jr. R.M., and Lasley R.D. The preischemic combination of the sodium-hydrogen exchanger inhibitor cariporide and the adenosine agonist AMP579 acts additively to reduce porcine myocardial infarct size. J Am Coll Surg 199 (2004) 586-594
8. Wajima T., Beguier B., and Yaguchi M. Effects of cariporide (HOE642) on myocardial infarct size and ventricular arrhythmias in a rat ischemia/reperfusion model: comparison with other drugs. Pharmacology 70 (2004) 68-73
9. Stevens R.M., Salik Jahania M., Mentzer Jr. R.M., and Lasley R.D. Sodium-hydrogen exchange inhibition attenuates in vivo porcine myocardial stunning. Ann Thorac Surg 77 (2004) 651-657
10. + exchanger inhibitor, cariporide against myocardial stunning in exercise-induced ischemia in dogs. Fundam Clin Pharmacol 12 (1998) 646-648
11. Symons J.D., and Schaefer S. Na(+)/H(+) exchange subtype 1 inhibition reduces endothelial dysfunction in vessels from stunned myocardium. Am J Physiol Heart Circ Physiol 281 (2001) H1575-H1582
12. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 269 (1994) 28584-28590
13. Kristof E., Szigeti G., Papp Z., et al. Cardiac responses to calcium sensitizers and isoproterenol in intact guinea pig hearts. Effects on cyclic AMP levels, protein phosphorylation, myoplasmic calcium concentration, and left ventricular function. Ann NY Acad Sci 853 (1998) 316-319
14. + channel in rat ventricular cells. J Pharmacol Exp Ther 283 (1997) 375-383
15. Kersten J.R., Montgomery M.W., Pagel P.S., and Warltier D.C. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 90 (2000) 5-11
16. Sonntag S., Sundberg S., Lehtonen L.A., and Kleber F.X. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 43 (2004) 2177-2182
17. Jamali I.N., Kersten J.R., Pagel P.S., Hettrick D.A., and Warltier D.C. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 85 (1997) 23-29
18. Kristof E., Szigeti G., Papp Z., et al. The effects of levosimendan on the left ventricular function and protein phosphorylation in post-ischemic guinea pig hearts. Basic Res Cardiol 94 (1999) 223-230
19. Wu D., Soong Y., Zhao G.M., and Szeto H.H. A highly potent peptide analgesic that protects against ischemia-reperfusion-induced myocardial stunning. Am J Physiol Heart Circ Physiol 283 (2002) H783-H791
20. Altman F.P. Tetrazolium salts and formazans. Prog Histochem Cytochem 9 (1976) 1-56
21. Kupatt C., Habazettl H., Hanusch P., et al. c7E3Fab reduces post-ischemic leukocyte-thrombocyte interaction mediated by fibrinogen. Implications for myocardial reperfusion injury. Arterioscler Thromb Vasc Biol 20 (2000) 2226-2232
22. Johnstone D.E., Janes R.D., Klassen G.A., and Armour J.A. Functional integrity of sympathetic efferent postganglionic axons in a region of stunned myocardium. Can J Cardiol 5 (1989) 357-364
23. Moalem J., Davidov T., Katz E., Scholz P.M., and Weiss H.R. Atrial natriuretic peptide reverses the negative functional effects of stunning in rabbit myocardium. Regul Pept 132 (2005) 47-52
24. Steinfath M., Chen Y.Y., Lavicky J., et al. Cardiac alpha 1-adrenoceptor densities in different mammalian species. Br J Pharmacol 107 (1992) 185-188
25. Steenbergen C., Perlman M.E., London R.E., and Murphy E. Mechanism of preconditioning. Ionic alterations. Circ Res 72 (1993) 112-125
26. Kivikko M., Lehtonen L., and Colucci W.S. Sustained hemodynamic effects of intravenous levosimendan. Circulation 107 (2003) 81-86
27. Eriksson O., Pollesello P., and Haikala H. Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion. J Cardiovasc Pharmacol 44 (2004) 316-321
28. Behrends M., and Peters J. The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts. Intensive Care Med 29 (2003) 1802-1807
29. De Luca L., Proietti P., Celotto A., et al. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J 150 (2005) 563-568
30. Garcia-Gonzalez M.J., Dominguez-Rodriguez A., and Ferrer-Hita J.J. Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: a series of cases. J Clin Pharmacol 45 (2005) 704-708
31. Ellger B.M., Zahn P.K., Van Aken H.K., Schmidt C., and Brussel T. Levosimendan: a promising treatment for myocardial stunning?. Anaesthesia 61 (2006) 61-63
32. Kivikko M., Antila S., Eha J., Lehtonen L., and Pentikainen P.J. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 40 (2002) 465-471
33. Lepran I., Pollesello P., Vajda S., Varro A., and Papp J.G. Preconditioning effects of levosimendan in a rabbit cardiac ischemia-reperfusion model. J Cardiovasc Pharmacol 48 (2006) 148-152
34. Du Toit E.F., Muller C.A., McCarthy J., and Opie L.H. Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 290 (1999) 505-514
35. Cammarata G.A., Weil M.H., Sun S., Huang L., Fang X., and Tang W. Levosimendan improves cardiopulmonary resuscitation and survival by K(ATP) channel activation. J Am Coll Cardiol 47 (2006) 1083-1085
36. Tsuchida A., Miura T., Miki T., et al. Critical timing of mitochondrial K(ATP) channel opening for enhancement of myocardial tolerance against infarction. Basic Res Cardiol 96 (2001) 446-453
37. De Hert S.G., Van der Linden P.J., Cromheecke S., et al. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology 101 (2004) 299-310
38. Tritapepe L., De Santis V., Vitale D., et al. Preconditioning effects of levosimendan in coronary artery bypass grafting-a pilot study. Br J Anaesth 96 (2006) 694-700
39. + exchanger for protection of the myocardium from lethal reperfusion injury. Cardiovasc Drugs Ther 16 (2002) 295-301
40. + exchange inhibitor cariporide (HOE 642) on cardiac function and cardiomyocyte cell death in rat ischaemic-reperfused heart. Clin Exp Pharmacol Physiol 27 (2000) 387-393
41. + exchange by cariporide reduces Na(+)-overload in ischemia and is cardioprotective. J Mol Cell Cardiol 31 (1999) 1985-1995
42. + exchange inhibitor, Hoe 642: difference from preconditioning in the role of protein kinase C. J Am Coll Cardiol 29 (1997) 693-701
43. + exchange inhibition in a regionally ischemic, reperfused porcine heart preparation with low residual blood flow. J Mol Cell Cardiol 30 (1998) 795-801
44. Ayoub I.M., Kolarova J., Yi Z., et al. Sodium-hydrogen exchange inhibition during ventricular fibrillation: beneficial effects on ischemic contracture, action potential duration, reperfusion arrhythmias, myocardial function, and resuscitability. Circulation 107 (2003) 1804-1809
45. Kolarova J.D., Ayoub I.M., and Gazmuri R.J. Cariporide enables hemodynamically more effective chest compression by leftward shift of its flow-depth relationship. Am J Physiol Heart Circ Physiol 288 (2005) H2904-H2911
46. Boyce S.W., Bartels C., Bolli R., et al. Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study. J Thorac Cardiovasc Surg 126 (2003) 420-427
47. Winkelmann B.R. American Heart Association scientific sessions. Expert Opin Invest Drugs 13 (2004) 435-445
48. ATP channel activation are additive in the isolated rat heart. Pflug Arch 447 (2003) 272-279
49. Davies J.E., Digerness S.B., Killingsworth C.R., et al. Multiple treatment approach to limit cardiac ischemia-reperfusion injury. Ann Thorac Surg 80 (2005) 1408-1416
50. Digerness S.B., Brookes P.S., Goldberg S.P., Katholi C.R., and Holman W.L. Modulation of mitochondrial adenosine triphosphate-sensitive potassium channels and sodium-hydrogen exchange provide additive protection from severe ischemia-reperfusion injury. J Thorac Cardiovasc Surg 125 (2003) 863-871